Table 1—

Baseline demographics and background characteristics of the randomized patient population

VariablePlaceboNateglinide 120 mgTroglitazone 600 mgNateglinide 120 mg and Troglitazone 600 mg
n148150151150
Sex (M/F %)59/4159/4163/3761/39
Race (%)
 Caucasian74.379.380.182.7
 Black10.16.07.92.7
 Asian/Oriental0.71.31.31.3
 Other14.913.310.613.3
Mean age (years)58585759
 Range32–8334–8333–8631–82
Mean BMI (kg/m2)
 Range20–3821–3819–3721–45
Mean duration of diabetes (years)4.75.14.24.2
 Range0.2–37.90.1–33.40–20.40.3–26.2
Mean HbA1c (%)8.28.48.18.3
 SD1.21.11.01.3
Mean fasting plasma glucose (mmol/l)10.410.910.310.5
 SD2.52.32.32.4